Bio-Rad Laboratories (NYSE: BIO) insider files to sell 776 shares under Rule 144

Rhea-AI Filing Summary

Bio-Rad Laboratories insider plans modest stock sale under Rule 144. A holder of Bio-Rad Laboratories, Inc. common stock has filed a notice of intent to sell 776 shares through Morgan Stanley Smith Barney LLC on the NYSE. The aggregate market value of the planned sale is listed as $247,978.56. The filing notes that 21,906,399 common shares were outstanding for the issuer at the time referenced in the form, providing context for the relatively small size of this transaction.

The shares to be sold come from restricted stock awards acquired from the issuer on three dates in early September 2022, in amounts of 264, 196, and 316 shares. The seller represents that they are not aware of any material nonpublic adverse information about the company’s current or prospective operations and acknowledges the criminal penalties that can apply to intentional misstatements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	776	247978.56	21906399	12/02/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2022	Restricted Stock	Issuer			264	09/01/2022	Not Applicable
Common	09/05/2022	Restricted Stock	Issuer			196	09/05/2022	Not Applicable
Common	09/03/2022	Restricted Stock	Issuer			316	09/03/2022	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for BIO indicate?

The Form 144 indicates that a holder of Bio-Rad Laboratories, Inc. (BIO) common stock intends to sell 776 shares under Rule 144 on the NYSE, with an aggregate market value of $247,978.56.

How large is the planned BIO share sale compared to shares outstanding?

The notice lists 21,906,399 common shares outstanding for Bio-Rad Laboratories, Inc., so the planned sale of 776 shares represents a very small portion of the total shares.

How were the BIO shares being sold acquired?

The shares to be sold are common stock acquired as restricted stock directly from the issuer on three dates in September 2022, in lots of 264, 196, and 316 shares.

Which broker is handling the planned BIO stock sale?

The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, as the broker for the planned sale of Bio-Rad Laboratories, Inc. common stock.

On which exchange will the BIO shares be sold?

The Form 144 states that the 776 common shares of Bio-Rad Laboratories, Inc. are intended to be sold on the NYSE.

What representation does the seller make in the BIO Form 144?

The seller represents that they do not know of any material adverse information about Bio-Rad Laboratories, Inc.’s current or prospective operations that has not been publicly disclosed and acknowledges that intentional misstatements can be a federal criminal violation.